On July 1, 2021 Shuwen Biotech reported that a partnership between the two companies for commercializing in China Uromonitor, a proprietary molecular test for detecting bladder cancer and monitoring bladder cancer recurrence through a non-invasive method (Press release, Shuwen Biotech, JUL 1, 2021, View Source [SID1234584752]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Under the terms of the agreement, Shuwen will distribute Uromonitor and offer testing services with Uromonitor in its CAP-accredited clinical labs in China.
Uromonitor is a CE-certified novel urine-based test for non-muscle invasive bladder cancer. It can be used for detecting the tumor in patients under recurrence surveillance or suspected of bladder cancer (e.g. hematuria), ancillary to cystoscopy and urine cytology. It has been validated in multicenter studies and exhibits high sensitivity and specificity.
"We are pleased to take on Uromonitor in China to offer bladder cancer patients and their physicians an innovative and accurate test for early diagnosis and early detection of cancer recurrence," commented Jay Z. Zhang, Chairman and CEO of Shuwen Biotech. "Uromonitor also adds to our growing portfolio of cancer testing products. And this partnership is another step towards our goal of benefiting patients with a full menu of the most innovative diagnostic tests for disease prevention, diagnosis and personalized treatment."
André Caldeira, VP of Stella Maris Medical Alerts, commented: "We are pleased to partner with Shuwen, a leading innovative diagnostic company in China. The collaboration with Shuwen provides us access to the Chinese market allowing Uromonitor to benefit Chinese patients. We hope that in the near future we will be able to drastically reduce cystoscopies in China."